Results 41 to 50 of about 390,088 (309)

Relationship between retinal fluid and visual acuity in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen: subgroup and post-hoc analyses from the ALTAIR study

Graefe's Archive for Clinical and Experimental Ophthalmology, 2021
To explore the relationship between retinal fluid status and best-corrected visual acuity (BCVA) in patients treated with intravitreal aflibercept (IVT-AFL) treat-and-extend (T&E) in the ALTAIR study. Outcomes were investigated according to overall fluid
M. Ohji, A. Okada, Koji Sasaki, SungChul Charles Moon, Tobias Machewitz, Kanji Takahashi   +5 more
semanticscholar   +1 more source

24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting

BMC Ophthalmology, 2017
Background To evaluate the clinical effectiveness and analyze the outcomes of a treat-and-extend (T&E) treatment regimen with ranibizumab for wet age-related macular degeneration (ARMD) in real life clinical settings over the first 2 years (24 months) of
Athanasios Vardarinos, Nitin Gupta, Raazia Janjua, Abigail Iron, Theo Empeslidis, Konstantinos T. Tsaousis   +5 more
doaj   +1 more source

Individualizing Therapy for Neovascular Age-Related Macular Degeneration with Aflibercept (VITAL): A Two-Year Prospective, Interventional Single-Centre Trial

Ophthalmology and Therapy, 2020
Aims To report the mean change in Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) and reading performance (reading acuity and maximum reading speed (MRS) using the MNREAD test) between baseline and 24 months in ...
Praveen J. Patel, Hari Jayaram, Maria Eleftheriadou, Clara Vazquez-Alfageme, Niaz Islam, Gary S. Rubin, Bishwanath Pal, Peter K. Addison, Robin Hamilton, Simona Degli Esposti   +9 more
doaj   +1 more source

Aflibercept for age-related macular degeneration: 4-year outcomes of a 'treat-and-extend' regimen with exit-strategy. [PDF]

, 2020
AIM: To report long-term outcomes on best-corrected visual acuity (BCVA) and treatment intervals with a treat-and-extend (T&E) regimen in patients with neovascular age-related macular degeneration (nAMD).
Munk, Marion, Zinkernagel, Martin, Jaggi, Damian, Nagamany, Thanoosha, Ebneter, Andreas, Wolf, Sebastian   +5 more
core   +2 more sources

Chondrosarcoma secondary to hereditary multiple exostosis treated by extended internal hemiplevectomy [PDF]

Sao Paulo Medical Journal, 1997
The authors report on the case of a 28-year-old patient with extensive chondrosarcoma of the left ischium and pubis involving hip joint, skin, and soft tissue of the gluteal region, secondary to hereditary multiple exostosis submitted to an extended internal Enneking type II and Ill hemipelvectomy. No prosthesis or arthrodesis was used. A few years ago,
Ademar Lopes, Sandra Morini, Leonardo José Vieira, Antonio Talvane de Oliveira   +3 more
openaire   +3 more sources

Prognostic factors in locally advanced colon cancer treated by extended resection [PDF]

Revista do Hospital das Clínicas, 2004
The impact of clinical, pathologic, and surgical variables on the postoperative morbidity, mortality, and survival of patients undergoing extended resections of colon carcinoma were evaluated. METHODS: The medical records of 95 patients who underwent extended resections for colon carcinoma between 1953 and 1996 were reviewed.
Vieira, René A.C., Lopes, Ademar, Almeida, Paulo A.C., Rossi, Benedito M., Nakagawa, Wilson T., Ferreira, Fabio O., Melo, Celso A.   +6 more
openaire   +4 more sources

Hodgkin Lymphoma on Hemodialysis Successfully Treated with Extended Courses of Brentuximab Vedotin

Case Reports in Oncology, 2022
Chemotherapy for hemodialysis (HD) patients is a challenging situation because HD patients are generally frail, and the pharmacokinetics and pharmacodynamics of most chemotherapeutics in HD patients are unknown. We report a classical Hodgkin lymphoma (cHL) patient successfully treated with 34 courses of brentuximab vedotin (BV) monotherapy, of which 30
Ayana Uchimura, Hajime Yasuda, Jun Ando, Yasunori Ota, Makoto Sasaki, Tomoiku Takaku, Yutaka Tsukune, Miyuki Tsutsui, Yoko Edahiro, Naoki Watanabe, Tomonori Ochiai, Norio Komatsu, Miki Ando   +12 more
openaire   +3 more sources

Outcomes when Switching from a pro re nata Regimen to a Treat and Extend Regimen Using Aflibercept in Neovascular Age-Related Macular Degeneration. [PDF]

, 2016
PURPOSE To investigate outcomes in patients with neovascular age-related macular degeneration (AMD) switched from a pro re nata regimen (PRN) to a treat and extend regimen (TER) under aflibercept. PROCEDURE Thirty-two patients were observed over
Giannakaki-Zimmermann, Helena, Munk, Marion, Zinkernagel, Martin, Ebneter, Andreas, Wolf, Sebastian   +4 more
core   +2 more sources

Primary lymphoma of the liver treated by extended hepatectomy and chemotherapy: a case report [PDF]

Revista do Hospital das Clínicas, 2002
Primary lymphoma of the liver is an extremely rare entity. A case of anaplastic large B-cell (both CD-20 and lambda positive) non-Hodgkin's lymphoma that was confined to the liver in a 33-year-old man is reported. The patient was treated with an extended right hepatectomy and combination chemotherapy: cyclophosphamide, adriamycin, vincristine, and ...
Eleazar, Chaib, Katia Ramos Moreira, Leite, Willian Abrão, Saad, Joaquim, Gama-Rodrigues   +3 more
openaire   +2 more sources

Treat and extend regimen with aflibercept for chronic central retinal vein occlusions: 2 year results of the NEWTON study

International Journal of Retina and Vitreous, 2019
Background To determine whether aflibercept (Eylea; Regeneron Pharmaceuticals, Inc., Tarrytown, NY) could continue to extend the macular edema free interval in patients on a treat and extend (TAE) with non-ischemic central retinal vein occlusions (CRVOs)
Rahul N. Khurana, Louis K. Chang, Alok S. Bansal, James D. Palmer, Chengqing Wu, Mark R. Wieland   +5 more
doaj   +1 more source